Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13 provide further evidence of its efficacy in treating CD30+ Hodgkin and non-Hodgkin lymphom
Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate.
The EU regulator has started a review of Novartis' PD-1 inhibitor tislelizumab – licensed from Chinese biotech BeiGene – for oesophageal and lung cancers, ahead of an FDA decision on the dr
Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the Europea
